Everolimus is a mammalian target of rapamycin complex 1 (mTORC1) inhibitor, approved internationally as an add‐on treatment for TSC‐associated refractory epilepsy, in addition to previous approval for the treatment of TSC‐associated subependymal giant cell astrocytomas and renal angiomyolipomas, and is understood to have a positive impact on abnormal brain cell growth as well as neural and synaptic activity in patients with TSC.36 This evidence concerns the gene TSC1 and astrocytoma (excluding glioblastoma).